The price of C4 Therapeutics Inc (NASDAQ: CCCC) closed at $11.00 in the last session, up 3.97% from day before closing price of $10.58. In other words, the price has increased by $+0.42 from its previous closing price. On the day, 2128109 shares were traded.
Ratios:
We take a closer look at CCCC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.34 and its Current Ratio is at 6.34. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On December 13, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $12.
Credit Suisse Upgraded its Underperform to Neutral on February 24, 2023, whereas the target price for the stock was revised from $12 to $10.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 754.61M and an Enterprise Value of 571.90M. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.35 while its Price-to-Book (P/B) ratio in mrq is 2.70. Its current Enterprise Value per Revenue stands at 27.55 whereas that against EBITDA is -4.47.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is 7.28, while the 200-Day Moving Average is calculated to be 3.85.
Shares Statistics:
According to the various share statistics, CCCC traded on average about 16.04M shares per day over the past 3-months and 3.23M shares per day over the past 10 days. A total of 60.47M shares are outstanding, with a floating share count of 53.47M. Insiders hold about 22.06% of the company’s shares, while institutions hold 63.53% stake in the company. Shares short for CCCC as of Feb 15, 2024 were 3.18M with a Short Ratio of 0.20, compared to 5.55M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.63% and a Short% of Float of 6.57%.
Earnings Estimates
The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.6, while EPS last year was -$0.71. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.28 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$1.08 and -$2.52 for the fiscal current year, implying an average EPS of -$1.85. EPS for the following year is -$1.92, with 8 analysts recommending between -$0.81 and -$3.01.
